Sanjay Godara, MD
Critical Care Medicine · Portsmouth, NHNPI 1841227113
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $883 of the $1,376 with a category attached, or 64.2%. Olympus Corporation Of The Americas accounts for 68.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $935 and has fallen 68.3% since, to $297 in 2025.
Across 24 payments — averaging $57.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$935
- Inspire Medical Systems, Inc.$149
- GSK$103
- Biogen$48
- AstraZeneca$32
- Philips North America LLC$27
- plus $81 from 5 others
What the payments were for
- Travel & lodging$88364%
- Food & beverage$47635%
- Education$171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 8 | $935 |
| Inspire Medical Systems, Inc. | 1 | $149 |
| GSK | 6 | $103 |
| Biogen | 2 | $48 |
| AstraZeneca | 1 | $32 |
| Philips North America LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Cala Health, Inc. | 1 | $17 |
| ZOLL Respicardia, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few critical care medicine providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 432 | $549,865 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $178,036 |
| OfevNintedanib Esylate | 13 | $172,330 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 14 | $146,855 |
| Breo ElliptaFluticasone/Vilanterol | 132 | $111,563 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $81,813 |
| Spiriva RespimatTiotropium Bromide | 85 | $80,781 |
| Fasenra PenBenralizumab | 11 | $63,689 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $49,831 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $49,526 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $27,899 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $24,620 |
| Spiriva HandihalerTiotropium Bromide | 21 | $22,155 |
| Arnuity ElliptaFluticasone Furoate | 29 | $10,373 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 221 | $9,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $103 | $781,513722 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $32 | $65,16469 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $18 | $1,16813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in New Hampshireon file to place this against a meaningful peer group, so we don't.
Other critical care medicine in Portsmouth
- Haney MallematLebanon$2K
- Eliza DeeryLaconia$820
- Jessica D'amicoNorth Conway$346
- Tariq NaseemLebanon$314
- Dawn BarclayLebanon$168
- Polina InkoulovaDover$135
- Christopher BrauerManchester$117
- Danira MayesManchester$97
- Eileen BishopLebanon$81
- Bjorn FloraNashua$67
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.